Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Cyclosporin A In Psoriatic Arthritis: An Open Study.
K. Steinsson, I. Jónsdóttir, H. Valdimarsson
Published 1990 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Eight patients with psoriatic arthritis entered an open study to determine the efficacy of oral cyclosporin A for their treatment. The starting dose was 3.5 mg/kg daily. Findings after the first six months are reported. One patient withdrew from the study after five months because of tremors, general malaise, and lack of improvement. Seven patients continued through the study, and marked improvement was found after two months in all clinical indices. The skin lesions improved in a parallel fashion. The cyclosporin A dose had to be reduced temporarily by 25% in three patients because of an increase in serum creatinine of more than 50%. A rise in diastolic blood pressure in three patients responded to treatment. The study suggests that cyclosporin A effectively treats arthritic manifestations of psoriasis as well as psoriatic skin lesions.
This paper references
Cyclosporin A treatment of refractory rheumatoid arthritis.
M. Weinblatt (1987)
Lymphocyte adhesion to psoriatic dermalcnd in is mediated by a tissue-specific receptor/ligand interaction
R Sackstein (1988)
Cyclosporin A in severe, treatment-refractory rheumatoid arthritis. A randomized study.
D. Yocum (1988)
Low Dose Cyclosporin in Rheumatoid Arthritis
A Seven‐Day variability study of 499 patients with peripheral rheumatoid arthritis
D. Mainland (1965)
Lympho - cyte adhesion to psoriatic dermal cnd in is mediated by a tissue - specific receptor / ligand interaction
R Sackstein (1988)
Cyclosporin A treatment ofrefractory rheumatoid arthritis
M E Weinblatt (1987)
Short‐term use of cyclosporin A in severe psoriasis
T. Joost (1986)
Lowdose cyclosporin A in severe psoriasis. A double blind study
Bos J D Joost Th Van (1988)
Low dose cyclosporine in rheumatoid arthritis: a pilot study.
P. Tugwell (1987)
Epidermal T lymphocytes and HLA‐DR expression in psoriasis
B. Baker (1984)
Cyclosporin improves psoriasis in double-blind study
C N Ellis (1986)
Low‐dose cyclosporin A in severe psoriasis. A double‐blind study
T. Joost (1988)
Psoriasis: a disease of abnormal Keratinocyte proliferation induced by T lymphocytes.
H. Valdimarsson (1986)
Sequence of changes in psoriatic epidermis. Immunocompetent cell redistribution precedes altered expression of keratinocyte differentiation markers.
W. Placek (1988)
Cyclosporine improves psoriasis in a double-blind study.
C. Ellis (1986)
A SEVEN-DAY VARIABILITY STUDY OF 499 PATIENTS WITH PERIPHERAL RHEUMATOID ARTHRITIS.
J. Deandrade (1965)
Side effects of systemic cyclosporine in patients not undergoing transplantation.
A. Palestine (1984)
Lymphocyte adhesion to psoriatic dermal endothelium is mediated by a tissue-specific receptor/ligand interaction.
R. Sackstein (1988)
Clearance of psoriasis with low dose cyclosporin.
C. E. Griffiths (1986)
Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis.
D. Ritchie (1968)
Cooperating clinics of the American Rheumatism Association. A seven-day variability study of499 patients with peripheral rheumatoid arthritis
This paper is referenced by
Termination of disease-modifying drugs in psoriatic arthritis: study of 109 courses of treatment.
C. Gómez-Vaquero (1996)
Therapy with cyclosporine in psoriatic arthritis.
I. Olivieri (1997)
Treatment of psoriatic arthritis with traditional DMARD’s and novel therapies: approaches and recommendations
A. Maharaj (2017)
Current and investigational treatment of psoriatic arthritis
R. Prasad (2004)
Opciones de tratamiento farmacológico actuales y futuras en la artritis psoriásica
T. Alonso (2001)
The use of cyclosporine in dermatology: part II.
C. Ryan (2010)
Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP
H. Fujita (2018)
Traitement du rhumatisme psoriasique et perspectives thérapeutiques
P. Goupille (2002)
Use of disease-modifying antirheumatic drugs in patients with psoriatic arthritis.
L. Marguerie (2002)
Pathogénie du rhumatisme psoriasique
F. Lioté (2002)
The use of ciclosporin in psoriasis
J. Berth-Jones (2005)
Psoriasisarthritis – eine bleibende Herausforderung für Rheumatologen und Patienten
S. Finzel (2011)
Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis.
M. Kraan (2002)
Psoriatic arthritis and arthroplasty: a review of the literature.
Ilya lofin (2008)
This information is current as Expansions that Appear Antigen Driven ClonalCharacterized by CD 8 and CD 4 T Cell Psoriatic Arthritis Joint Fluids Are
Patrick J. Costello (2001)
Behandling av psoriasis - Bakgrundsdokumentation
M. Ståhle (2006)
Nail lesions in psoriatic arthritis: recovery with sulfasalazine treatment
J. Gerster (2002)
Cyclosporine in nonpsoriatic dermatoses.
V. Ho (1990)
Clinical and synovial tissue studies in psoriatic arthritis
A. V. Kuijk (2010)
Sonography as a replacement for sialography for the diagnosis of salivary glands affected by Sjögren's syndrome
K. Yonetsu (2002)
Treatment of psoriatic arthropathy.
P. Goupille (1992)
I. Bruce (2012)
The course of psoriasis
E. D. Jong (1997)
The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review
C. Chighizola (2016)
The case for cyclosporin a in psoriatic arthritis
K. Steinsson (2007)
Spondylarthropathies: options for combination therapy
A. Tubergen (2009)
Treatment of psoriatic arthritis.
M. Cuellar (1994)
Nail lesions in psoriatic arthritis : recovery with sulfasalazine treatment
Y. Takagi (2002)
Infliximab in psoriatic arthritis
A. Anandarajah (2007)
Evidence for susceptibility determinant(s) to psoriasis vulgaris in or near PTPN22 in German patients
U. Hüffmeier (2005)
Long-term safety and efficacy of low-dose cyclosporin A in severe psoriatic arthritis
P. Sarzi-Puttini (2001)See more